PMID- 15000295
OWN - NLM
STAT- MEDLINE
DCOM- 20041007
LR  - 20191108
IS  - 1064-1963 (Print)
IS  - 1064-1963 (Linking)
VI  - 26
IP  - 1
DP  - 2004 Jan
TI  - Hypotensive and prophylactic effects of angiotensin II subtype 1 receptor 
      antagonist, irbesartan, in stroke-prone spontaneously hypertensive rats.
PG  - 27-42
AB  - We determined the acute hypotensive effect of a single administration and the 
      prophylactic effect of chronic treatment with Irbesartan, an angiotensin II 
      receptor antagonist, on the development of end-organ damage in stroke-prone 
      spontaneously hypertensive rats (SHRSP). The acute hypotensive effect was 
      determined by a telemetrical method in SHRSP fed a normal diet. The prophylactic 
      effect was examined by biochemical, histopathological and immunohistochemical 
      methods in SHRSP fed a high-salt and low-protein diet. Irbesartan (3, 10, 30 and 
      100 mg/kg) reduced blood pressure in a dose-dependent manner without affecting 
      heart rate. Irbesartan (3, 10 and 30 mg/kg) increased the survival rate in SHRSP 
      fed a high-salt and low-protein diet. Furthermore, Irbesartan ameliorated the 
      appearance of stroke symptoms in dose-dependent manner showing association with 
      the prevention of microscopic lesions. Irbesartan ameliorated the increases in 
      urinary protein excretion and N-acetyl-D-glucosamidase activity by preventing 
      nephrosclerosis, as judged by microscopic observations, and ameliorated the 
      increases in the expression of collagen IV and fibronectin in the kidney. These 
      findings demonstrate that Irbesartan is a potent antihypertensive drug offering a 
      protective effect on the development of hypertension-induced end-organ damages in 
      SHRSP. Thus, Irbesartan is useful for the therapy of hypertension with end-organ 
      damage.
FAU - Shimamura, Toshitake
AU  - Shimamura T
AD  - Discovery Research Laboratories, Shionogi & Co., Ltd., Toyonaka, Osaka, Japan. 
      toshitake.shimamura@shionogi.co.jp
FAU - Masui, Masao
AU  - Masui M
FAU - Torii, Mikinori
AU  - Torii M
FAU - Nakajima, Masatoshi
AU  - Nakajima M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Clin Exp Hypertens
JT  - Clinical and experimental hypertension (New York, N.Y. : 1993)
JID - 9305929
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Receptor, Angiotensin, Type 1)
RN  - 0 (Tetrazoles)
RN  - J0E2756Z7N (Irbesartan)
SB  - IM
MH  - *Angiotensin II Type 1 Receptor Blockers
MH  - Animals
MH  - Antihypertensive Agents/*administration & dosage
MH  - Biomarkers/blood/urine
MH  - Biphenyl Compounds/*administration & dosage
MH  - Blood Pressure/drug effects
MH  - Body Weight/drug effects
MH  - Brain/anatomy & histology/drug effects
MH  - Diastole/drug effects
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Heart/anatomy & histology/drug effects
MH  - Heart Rate/drug effects
MH  - Hypertension/mortality/pathology/*physiopathology
MH  - Immunohistochemistry
MH  - Irbesartan
MH  - Kidney/anatomy & histology/drug effects/metabolism
MH  - Male
MH  - Models, Cardiovascular
MH  - Organ Size/drug effects
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Receptor, Angiotensin, Type 1/*administration & dosage
MH  - Stroke/mortality/pathology/*physiopathology
MH  - Survival Analysis
MH  - Systole/drug effects
MH  - Tetrazoles/*administration & dosage
EDAT- 2004/03/06 05:00
MHDA- 2004/10/08 09:00
CRDT- 2004/03/06 05:00
PHST- 2004/03/06 05:00 [pubmed]
PHST- 2004/10/08 09:00 [medline]
PHST- 2004/03/06 05:00 [entrez]
AID - 10.1081/ceh-120027329 [doi]
PST - ppublish
SO  - Clin Exp Hypertens. 2004 Jan;26(1):27-42. doi: 10.1081/ceh-120027329.